Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells ...
Commercialization ready compound supports a new method of generating highly functional human CAR-T cells for treating infectious diseases and cancer In experimental models, human CAR-T cells manufactu ...
Initiated US Phase 1/2a study of DLL3-targeting 212Pb-based Radio-DARPin candidate MP0712 for SCLC and other neuroendocrine cancers, co-developed ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD ...
Operator: Hello, and thank you for standing by. Welcome to Allogene Therapeutics, Inc. Fourth Quarter 2025 Conference Call.
Barclays 28th Annual Global Healthcare Conference March 11, 2026 1:30 PM EDTCompany ParticipantsAnthony Pagano - Executive VP ...
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results